Sign in
CompletedPhase 4

Study on the Efficacy and Safety of Tongluo Kaibi Tablets in the Treatment of Fibromyalgia Syndrome

Key facts

Who runs it
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
150 people enrolled
Started
1 Jan 2024
Ended
1 Mar 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tongluo Kaibi Tablet
  • Pregabalin capsule
Record updated
17 July 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • Aged 18 to 75 years at the time of informed consent acquisition, regardless of gender
  • Meet the 2016 fibromyalgia classification criteria established by the American College of Rheumatology
  • Score ≥4 on the Visual Analogue Scale for Pain (Pain VAS) at screening
  • Agree to receive 8 weeks of treatment and related examinations, and sign the informed consent form
  • No medication for fibromyalgia, or the types and dosages of medications for fibromyalgia have remained stable for at least 2 weeks

Who cannot take part

  • Allergic constitution, or hypersensitivity to the investigational product Tongluo Kaibi Tablets, pregabalin capsules, excipients or similar ingredients; Suspected or confirmed history of alcohol or substance abuse
  • Receiving Tongluo Kaibi Tablets at enrollment
  • Participation in any other clinical trial within 3 months prior to enrollment
  • Have a medical history or confirmed diagnosis of any of the following conditions during screening: severe cardiovascular and cerebrovascular diseases; combined diabetes, malignant tumors, hematological diseases, inflammatory arthritis or other severe progressive systemic diseases; other psychiatric disorders leading to inability or unwillingness to cooperate with the trial
  • Any other conditions judged by investigators to render the subject unsuitable for this clinical trial
  • Any laboratory test result before screening meets the following criteria: liver and renal function tests show ALT or AST > 2 times the upper limit of normal (ULN), or creatinine (Cr) > 1.2 times ULN (refer to the normal reference range of the laboratory at each study center); other clinically significant abnormal laboratory parameters judged by investigators to disqualify subjects from enrollment
  • Pregnant or lactating women, women planning pregnancy in the near future, or those unwilling to adopt contraceptive measures

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Fibromyalgia is a chronic, disabling musculoskeletal pain disorder. Pregabalin is the sole pharmaceutical agent approved for the treatment of fibromyalgia in China. Tongluo Kaibi Tablet, an approved proprietary Chinese medicine with collaterals-dredging and blood-activating effects, has demonstrated potential therapeutic benefits for fibromyalgia in preliminary small-scale observational studies, yet high-quality large-sample clinical evidence remains lacking. This multicenter, randomized, double-blind, double-dummy parallel-controlled clinical trial was conducted to evaluate the clinical efficacy and safety of Tongluo Kaibi Tablet in patients with fibromyalgia syndrome.

The 2 groups in the trial

  • Tongluo Kaibi Tablet groupTreatment being tested

    Tongluo Kaibi Tablets, 0.9 g per dose, once daily; pregabalin matching placebo, 150 mg per dose, once daily. After one week, the dose of pregabalin matching placebo will be titrated up to 150 mg twice daily if tolerated by patients. For patients with poor tolerance, the dosage shall remain 150 mg once daily for a total treatment period of 8 weeks.

    Treatment: Tongluo Kaibi Tablet

  • Pregabalin Capsule GroupExisting treatment, for comparison

    Tongluo Kaibi Tablet matching placebo, 0.9 g per dose, once daily; pregabalin capsules, 150 mg per dose, once daily. After one week, the dose of pregabalin capsules will be titrated up to 150 mg twice daily if tolerated by patients. For patients with poor tolerance, the dosage shall remain 150 mg once daily for a total treatment period of 8 weeks.

    Treatment: Pregabalin capsule

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-Blind Study on the Efficacy and Safety of Tongluo Kaibi Tablets in the Treatment of Fibromyalgia Syndrome
Record updated
17 July 2026